---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-037974"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2024-08-21T23:59:59+00:00"
generated_at: "2026-05-31T08:17:10.144648+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BridgeBio forms GondolaBio JV with $300M investor commitment; retains 45% stake

## Summary
- BridgeBio contributed early-stage programs for Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex.
- Investors including Viking Global, Patient Square, Sequoia, Frazier, Cormorant, and Aisling committed $300M in tranches.
- CEO Neil Kumar's entity also invested; BridgeBio's initial interest ~45%, subject to dilution.
- Special committee of independent directors approved with Goldman Sachs as financial advisor.
- JV will research, develop, manufacture and commercialize the contributed programs.

## SEC filing metadata
- accession: 0001140361-24-037974
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2024-08-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036124037974/0001140361-24-037974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036124037974/ef20034419_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-037974
- JSON: https://secwatch.observer/filing/0001140361-24-037974.json
- Plain text: https://secwatch.observer/filing/0001140361-24-037974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.